SCHEMBL23244347

SCHEMBL23244347

O=C(Cc1ccccc1)N1CCN(c2ccc(O)cc2F)CC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.72
ALDH1A1 P00352 5/20 0.69
MAPT P10636 4/20 0.69
SMN1; SMN2 Q16637 3/20 0.69
POLB P06746 2/20 0.69
ME2 P23368 3/20 0.64
ME1 P48163 3/20 0.64
ME3 Q16798 3/20 0.64
L3MBTL1 Q9Y468 2/20 0.63
HPGD P15428 1/20 0.63
GRM5 P41594 2/20 0.61
LMNA P02545 3/20 0.60
HTT P42858 2/20 0.60
ALOX15 P16050 1/20 0.60
HSD17B10 Q99714 1/20 0.60
TDP1 Q9NUW8 1/20 0.57
ALOX12 P18054 2/20 0.52
GAA P10253 1/20 0.52
MEN1 O00255 1/20 0.51
TSHR P16473 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29576156 1.00 KMT2A (0.72) KMT2AALDH1A1MAPTSMN1; SMN2POLB
SCHEMBL20521279 0.82 MAPT (0.58) KMT2AALDH1A1MAPTSMN1; SMN2POLB
SCHEMBL4133081 0.81 GRM5 (0.48) KMT2AALDH1A1MAPTSMN1; SMN2POLB
SCHEMBL23244223 0.78 ME3 (1.00) KMT2AALDH1A1MAPTPOLBME2
SCHEMBL10722408 0.77 HSD11B1 (0.77) KMT2AALDH1A1MAPTSMN1; SMN2ME2
SCHEMBL3967794 0.77 HSD11B1 (0.77) KMT2AALDH1A1MAPTSMN1; SMN2ME2
SCHEMBL2766780 0.76 ADRA1D (0.54) KMT2AALDH1A1MEN1
SCHEMBL3796463 0.76 KMT2A (0.77) KMT2AALDH1A1MAPTSMN1; SMN2POLB
SCHEMBL1902513 0.76 GRM5 (1.00) KMT2AALDH1A1MAPTSMN1; SMN2POLB
SCHEMBL11157921 0.75 GRM5 (0.69) KMT2AALDH1A1MAPTME2ME1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220127266-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2022-04-28 US claimed
WO-2021074898-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2021-04-22 WO claimed
US-20210115038-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2021-04-22 US claimed
US-20220127266-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2022-04-28 US disclosed
US-20220127266-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2022-04-28 US disclosed
US-11225480-B2 Malic enzyme inhibitors SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2022-01-18 US disclosed
US-11225480-B2 Malic enzyme inhibitors SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2022-01-18 US disclosed
WO-2021074898-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2021-04-22 WO disclosed
WO-2021074898-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2021-04-22 WO disclosed
US-20210115038-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2021-04-22 US disclosed
US-20210115038-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2021-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210115038-A1 MALIC ENZYME INHIBITORS ME1, ME2, ME3 KMT2A 1797/4885ALDH1A1 144/4885MAPT 2817/4885
US-11225480-B2 Malic enzyme inhibitors ME1, RNASE1, ME2 KMT2A 1091/4885ALDH1A1 89/4885MAPT 3825/4885
US-20220127266-A1 MALIC ENZYME INHIBITORS ME1, ME2, ME3 KMT2A 1797/4885ALDH1A1 144/4885MAPT 2817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.